MyoKardia's mission is to revolutionize the treatment of genetic cardiomyopathies and related heart disease through exploiting advances in sarcomere-related biochemistry and molecular biology.

MyoKardia is developing a pipeline of novel, small molecule therapeutics that address key clinical needs for patients with genetic heart disease.

Learn More

News & Events

MyoKardia Appoints Biotech Veteran Mark L. Perry to Board of Directors

Read More

MyoKardia Appoints Tassos Gianakakos to Chief Executive Officer

Read More

MyoKardia Appoints Industry Veteran Jonathan Fox, M.D., Ph.D., as Chief Medical Officer

Read More